Genitourinary Cancers

Patients with previously treated metastatic urothelial bladder cancer had response rates that exceeded historical standards when treated with an investigational immunotherapeutic agent, updated results of a large phase 2 clinical trial showed. Treatment with the PD-1 ligand 1 (PD-L1) inhibitor atezolizumab led to an overall response rate of 15% in 311 patients, including a 26% rate among patients who had the highest levels of PD-L1 expression. Historical data have demonstrated response rates of about 10% for second-line therapy and beyond. Read More ›

Real-World Data Show 2-Year Survival Predicts Long-Term Survival for Metastatic Germ-Cell Testicular Cancer

By Phoebe Starr

Contemporary treatment has led to improvements in survival for all patients with metastatic testicular germ-cell tumors (GCTs), including poor-risk patients, although they still have worse survival. A new study shows that if poor-risk patients receive curative therapy and survive for at least 2 years, their survival approaches that of favorable-risk and intermediate-risk patients. The study supports no further routine scanning 2 years after diagnosis in surviving patients. Read More ›

Reirradiation of Pelvic Area Is Safe and Improves Quality of Life

By Phoebe Starr

Genitourinary Cancers

Experience at a high-volume cancer center suggests that nonstereotactic body radiotherapy external beam reirradiation of the pelvis for cancer recurrence or for a second genitourinary malignancy is safe in patients with advanced cancer, and can achieve excellent and durable palliation of symptoms without severe radiation-induced morbidity. Read More ›

Genitourinary Cancers

December 2021, Vol 9, No 1

Subscribe to
Rheumatology Practice Management

I'd like to receive:

Genitourinary Cancers

December 2021, Vol 9, No 1

Subscribe to Rheumatology Practice Management

I'd like to receive:

Subscribe to
Rheumatology Practice Management